[232]
Apotex seeks to reweigh the various factors in the obviousness test. The motivation evidence is no different than that in the
Novopharm
Trial. Apotex, like Novopharm, relies on the evidence that in 1985 four competitors came to levofloxacin shortly after Daiichi. Justice Hughes considered this same evidence and held that there was no evidence that any competitor chose to exploit ofloxacin. (
Novopharm
Trial, above at paras. 67, 114(5).)